Wakefield, MA – According to filings with the U.S. Securities and Exchange Commission, Myrtelle is raising $30,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Pykett played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Myrtelle
Myrtelle is a gene therapy company whose mission is to transform the treatment of neurological diseases. Through our core technologies, assets, patents, and expertise, we have built a platform to address an array of diseases with white matter involvement, including demyelinating diseases and ASPA-associated disorders.

To learn more about Myrtelle, visit http://myrtellegtx.com/

Contact:
Mark Pykett, Chief Executive Officer
781-621-2381
https://www.linkedin.com/in/mark-pykett-0171b99/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved